Sample size calculation for randomized trials via inverse probability of response weighting when outcome data are missing at random.
Harrison LJ, Wang R.
Stat Med. 2023 Mar 06. PMID: 36880120
Education and Training
MMATH, 2006, Mathematics
University of Oxford, UK
MSc, 2007, Medical Statistics
London School of Hygiene and Tropical Medicine, UK
PhD, 2021, Biostatistics
Harvard Graduate School of Arts and Sciences, Boston, MA
Bibliography
Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019.
Li Y, Harrison LJ, Chew KW, Currier JS, Wohl DA, Daar ES, Evering TH, Wu R, Giganti M, Ritz J, Javan AC, Coombs RW, Moser C, Hughes MD, Eron JJ, Smith DM, Li JZ.
Clin Infect Dis. 2023 02 18. 76(4):734-737. PMID: 36210483
Signature biomarker states and mortality among hospitalized SARS-CoV-2-infected patients.
Selvaggi C, Harrison LJ, Kim E, Reilly MP, Foulkes AS.
J Nephrol. 2022 04. 35(3):765-767. PMID: 34989977
Power calculation for analyses of cross-sectional stepped-wedge cluster randomized trials with binary outcomes via generalized estimating equations.
Harrison LJ, Wang R.
Stat Med. 2021 12 20. 40(29):6674-6688. PMID: 34558112
Power calculation for cross-sectional stepped wedge cluster randomized trials with variable cluster sizes.
Harrison LJ, Chen T, Wang R.
Biometrics. 2020 09. 76(3):951-962. PMID: 31625596
Quality of life improvement in resource-limited settings after one year of second-line antiretroviral therapy use among adult men and women.
Torres TS, Harrison LJ, La Rosa AM, Cardoso SW, Zheng L, Ngongondo M, Some F, Lalloo UG, Mwelase T, Collier AC, Hughes MD.
AIDS. 2018 03 13. 32(5):583-593. PMID: 29334547
Quality of life among HIV-infected individuals failing first-line antiretroviral therapy in resource-limited settings.
Torres TS, Harrison LJ, La Rosa AM, Lavenberg JA, Zheng L, Safren SA, Ngongondo M, Poongulali S, Matoga M, Samaneka W, Collier AC, Hughes MD.
AIDS Care. 2018 08. 30(8):954-962. PMID: 29343078
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.
Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, Salantes DB, Seamon CA, Scheinfeld B, Kwan RW, Learn GH, Proschan MA, Kreider EF, Blazkova J, Bardsley M, Refsland EW, Messer M, Clarridge KE, Tustin NB, Madden PJ, Oden K, O'Dell SJ, Jarocki B, Shiakolas AR, Tressler RL, Doria-Rose NA, Bailer RT, Ledgerwood JE, Capparelli EV, Lynch RM, Graham BS, Moir S, Koup RA, Mascola JR, Hoxie JA, Fauci AS, Tebas P, Chun TW.
N Engl J Med. 2016 11 24. 375(21):2037-2050. PMID: 27959728
Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251.
Robbins GK, Cohn SE, Harrison LJ, Smeaton L, Moran L, Rusin D, Dehlinger M, Flynn T, Lammert S, Wu AW, Safren SA, Reynolds NR.
HIV Clin Trials. 2016 07. 17(4):165-72. PMID: 27347650
CCR5-?32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.
Henrich TJ, Hanhauser E, Harrison LJ, Palmer CD, Romero-Tejeda M, Jost S, Bosch RJ, Kuritzkes DR.
J Infect Dis. 2016 Mar 01. 213(5):766-70. PMID: 26512140